Aim: Safety and efficacy of vortioxetine (5-20 mg/ day) in Japanese patients with major depressive disorder were evaluated in two phase 3 studies consisting of a short-term, 8-week, placebo-controlled, double-blind study followed by a long-term, 52-week, open-label extension study.
M AJOR DEPRESSIVE DISORDER (MDD) is a chronic, recurring disease with considerable morbidity in the general population. 1 The estimated lifetime prevalence of MDD ranges from 1% to 16.9% globally, 1 and the 12-month prevalence of MDD in Japan is reportedly 2.9%. 2 The clinical, neurobiological, and genetic heterogeneity of MDD makes it an overall challenging condition to treat. The deficiency of neurotransmitters serotonin 5-hydroxytryptamine (5-HT) and norepinephrine has been associated with the pathogenesis of MDD, and commonly used antidepressants, such as selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI), have demonstrated efficacy in patients with MDD. 3 However, remission rates with SSRI and SNRI are approximately 30% and about 33% of patients experience treatment-resistant depression after several consecutive treatment trials. 4 In addition, SSRI and SNRI have a slow onset of action and can cause sideeffects, such as sexual dysfunction, sleep disturbances, weight gain, and nausea, which may affect treatment adherence and health-related quality of life. 5, 6 There is a need for new antidepressants with a mechanism of action different from that of SSRI and SNRI to improve efficacy across multiple symptom domains, reduce side-effects, and provide early and sustained remission. Multitarget approaches appear more promising than selective agents with a monoaminergic mechanism of action. 7 Vortioxetine (Lu AA21004) is an antidepressant with a novel multimodal mechanism of action that combines direct modulation of multiple serotonergic receptor activity and inhibition of the 5-HT transporter. 8 Vortioxetine is a 5-HT 3 , 5-HT 7 , and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, and 5-HT 1A receptor agonist, in addition to a 5-HT transporter inhibitor. 8, 9 Nonclinical data suggest that vortioxetine modulates direct and indirect multiple neurotransmitters in the brain, including serotonin, norepinephrine, dopamine, histamine, acetylcholine, γ-aminobutyric acid (GABA), and glutamate. 8, [10] [11] [12] Vortioxetine's multimodal mechanism of action implies a differentiated profile from conventional antidepressants. 8 Phase 2 and 3 clinical trials conducted in the USA and Europe have demonstrated the antidepressant efficacy of vortioxetine in MDD patients at doses of up to 20 mg/day. 13, 14 Vortioxetine was generally safe and well tolerated. 13 Vortioxetine is currently approved for use in the treatment of MDD worldwide, including in North, Central, and South America, Europe, as well as Southeast Asia. The clinical development program of vortioxetine comprises 17 short-term studies, five long-term extension studies, and a 12-month relapse-prevention study. To date, no long-term safety data in Japanese MDD patients are available. Here, we describe for the first time the results of two phase 3 studies in Japanese MDD patients. The first study assessed the short-term efficacy and safety of vortioxetine (5 mg and 10 mg) once daily compared with placebo. The second phase 3 extension study evaluated the long-term safety and efficacy of flexible doses of 5 mg, 10 mg, or 20 mg vortioxetine up to 52 weeks.
METHODS
The short-term study was a randomized, doubleblind, placebo-controlled, parallel-group, phase 3 study to assess the efficacy and safety of 8-week treatment of two fixed doses of vortioxetine (5 and 10 mg/day) in Japanese patients with MDD. Patients who had completed the 8-week doubleblind treatment period with improvement in the Clinical Global Impression Scale-Severity (CGI-S) score of at least 1 point from baseline had the option to continue in an open-label, flexible-dose, long-term, phase 3 extension study to assess the safety and efficacy of continuous vortioxetine treatment up to 52 weeks.
Ethics statement
Institutional review boards constituted according to the Japanese regulatory requirements were responsible for the review and approval of the clinical studies according to the requirements of the International Conference on Harmonisation Guideline for Good Clinical Practice and the Declaration of Helsinki. Participants provided written informed consent before undergoing any study procedures and were capable of understanding and complying with protocol requirements.
Study participants
Patients aged 20-75 years were eligible for both studies if they had a primary diagnosis of MDD according to the DSM-IV-TR criteria with a current major depressive episode (MDE) of at least 3 months, a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥ 26, and a CGI-S score ≥ 4. Patients were only eligible to participate in the long-term open-label extension study if they completed the double-blind treatment period with improvement in CGI-S score of at least 1 point from baseline.
Patients were ineligible for entry into either study if they had any current psychiatric disorder other than MDD, any clinically significant neurological disorder, any substance-related disorder (except nicotine and caffeine-related disorders), or a confirmed positive urine drug screen. Participants were excluded if their depressive symptoms were resistant to at least two adequate antidepressant treatments of 6 weeks' duration each or were at significant risk of suicide defined by a score of ≥ 5 on Item 10 (Suicidal Thoughts) of the MADRS or had attempted suicide within 6 months. Patients who had recently taken or were anticipated to take disallowed concomitant medication, had recently received any investigational compound, or had previously received vortioxetine were ineligible for participation. Patients were also excluded from both studies if they had abnormal vital signs, laboratory values, or electrocardiogram (ECG), received electroconvulsive, vagal nerve stimulation, or repetitive transcranial magnetic stimulation therapy within 6 months, or were currently receiving cognitive/behavioral therapy or systematic psychotherapy, or planned to initiate such therapy during the study. Patients with any DSM-IV-TR axis II disorder that might compromise the study, chronic liver disease, a history of severe drug allergy or hypersensitivity, or clinically significant unstable illness were ineligible. Women who were pregnant or lactating or who intended to become pregnant during the study were excluded. In addition, participants who had developed an adverse event (AE) or any abnormality at the end of the 8-week double-blind treatment period and were considered as having potential safety risks with continuous treatment were excluded from the long-term open-label study.
Study design
The two phase 3 studies described here occurred between 2011 and 2013 and included a short-term study evaluating the efficacy and safety of vortioxetine (5 mg and 10 mg) once daily compared with placebo as well as a second phase 3 open-label extension study evaluating the long-term safety and efficacy of flexible doses of 5 mg, 10 mg, or 20 mg vortioxetine up to 52 weeks. The short-term study consisted of a 1-week screening period, an 8-week double-blind treatment period, a 2-week singleblind discontinuation period, and a safety follow-up of 4 weeks after receiving the last dose (Fig. 1) . During the double-blind treatment period, a randomization code was generated and patients were randomly assigned in a 1:1:1 ratio to placebo, 5 mg vortioxetine, or 10 mg vortioxetine once daily for 8 weeks. All randomization information was stored in a secured area, accessible only to authorized personnel. There were 57 individual study sites for the short-term study and 44 individual study sites for the extension study. Patients visited study sites at weeks 1 and 2 and every 2 weeks thereafter.
Patients who prematurely discontinued the 8-week double-blind treatment period were requested to visit the study site for end-of-study assessments as soon as possible. Those patients who completed the 8-week period but did not enroll in the open-label study received placebo in a single-blind manner for 2 weeks. Potential discontinuation symptoms were assessed weekly. Patients who completed the 8-week double-blind treatment period with at least 1-point improvement in the CGI-S score from baseline were eligible for immediate enrollment in the 52-week open-label extension study without entering the discontinuation period.
During the open-label extension study, patients received 10 mg/day of vortioxetine, starting the day after the completion of the double-blind treatment period in the preceding short-term study (Fig. 1) . After 2 weeks, the dose could be decreased to 5 mg/ day or increased to 20 mg/day based on response to the study drug or appearance of symptoms. The dose could only be increased if the CGIImprovement (CGI-I) score had increased (worsened) by at least 1 point since the previous visit or the patient's CGI-S score indicated 'Mildly ill,' 'Moderately ill,' 'Markedly ill,' 'Severely ill,' or 'Among the most extremely ill,' and in the opinion of the investigator, dose escalation would benefit the patient. If changed, the dose was maintained for at least 2 weeks except in emergencies that required immediate dose reduction for safety reasons. A dose increase from 5 mg/day to 20 mg/day or a dose decrease directly from 20 mg/day to 5 mg/day was not allowed.
Patients visited study sites biweekly in the first month and every 4 weeks subsequently. A safety follow-up contact was made 4 weeks after completion of the 52-week treatment period. For patients who prematurely discontinued either study, a safety follow-up contact was made 4 weeks after the last dose of the study drug whenever possible.
For the short-term study, it was calculated that 360 patients (120 patients per arm) were required to give at least 80% power to detect a difference by a two-sample t-test at 5% significance level (2-sided). This estimation was determined by assuming that a common standard deviation (SD) for the change from baseline in MADRS total score is 8.2, and a difference between each vortioxetine group (5 mg and 10 mg/day) and placebo group is 3.0. For the open-label extension study, the number of eligible patients was estimated to be 249 by assuming that 85% of the patients would complete the 8-week double-blind treatment period of the preceding short-term study, and among them, 85% in the 5-and 10-mg vortioxetine group and 75% in the placebo group would be eligible to participate in the long-term study (CGI-S score improved by at least 1 point compared to baseline of the short-term study). Assuming that 50% of these 249 patients were willing to participate in this study, and 90% of them met the eligibility criteria, the number of patients participating in the long-term study was estimated to be 111. This sample size was expected to give at least 80% power to detect the difference by a two-sample t-test at 5% significance level (2-sided). Under these assumptions, the power for the overall F-test was 83%.
Efficacy evaluation
The primary efficacy end-point for the short-term study was change from baseline in MADRS total score after 8 weeks of double-blind treatment. For the full analysis set, an analysis of covariance (ANCOVA) model with the change in MADRS total score as a dependent variable, treatment as a fixed effect, and the baseline MADRS total score as a covariate was applied for comparisons between placebo and the vortioxetine treatment arms. Fisher's least significant difference (LSD) procedure was used for adjustment for multiplicity. The overall F-test Completed study with at least 1-point improvement in CGI-S score from baseline
Open-label treatment period
Completion of doubleblind treatment period Figure 1 . Study designs of the short-and long-term treatment periods. Patients were randomized the day before the first study drug administration. Patients who completed the short-term study but did not enroll in the extension study were assessed for potential discontinuation symptoms over the next 2 weeks. Patients who completed the double-blind treatment period with improvement in the Clinical Global Impression Scale-Severity (CGI-S) score of at least 1 point from baseline were eligible for immediate enrollment in the open-label extension study. The first visit of the open-label extension study was identical to the end-of-treatment visit of the 8-week double-blind treatment period in the preceding short-term study. Patients visited study sites biweekly in the first month and every 4 weeks subsequently. Safety follow-up assessments were conducted as a visit to the site or as a telephone contact for both studies 4 weeks after completion of the treatment period or 4 weeks after the last dose of study drug in patients who prematurely discontinued. PBO, placebo; QD, once daily; VOR, vortioxetine.
was conducted based on the above-mentioned model. Comparisons between placebo and each vortioxetine group as well as between the vortioxetine 5-mg and 10-mg groups were conducted only if the overall F-test was statistically significant. The last observation carried forward (LOCF) was the pre-specified method to account for missing data. In addition, changes from baseline in MADRS total score were analyzed using the mixed model for repeated measurements (MMRM) as the secondary analysis.
Secondary efficacy end-points for the short-term study were MADRS response (≥ 50% decrease in the MADRS total score from baseline) and MADRS remission (MADRS total score ≤ 10) at week 8 (LOCF), compared between treatment groups using logistic regression analysis, including baseline MADRS total score and treatment arm in the model. Change from baseline in the Hamilton Depression Scale (HAM-D17) total score, Sheehan Disability Scale (SDS) total score, and CGI-I score at week 8 were determined using the LOCF method. Efficacy end-points for the long-term study were change in MADRS total score and CGI-S score evaluated at each study visit from the baseline at the beginning of the long-term extension study and the CGI-I score at each time-point it was assessed. The primary endpoint of the long-term study was safety assessment (adverse events, laboratory values, bodyweight, vital signs, ECG, and physical examination findings).
Safety evaluation
AE, treatment-emergent adverse events (TEAE), laboratory values, bodyweight, vital signs, ECG, and physical examination findings were evaluated at every study visit for both studies. Suicidal ideation and behavior were assessed using the Columbia Suicide Severity Rating Scale (C-SSRS).
RESULTS

Study participants
Of the 447 patients screened, 366 were randomized to the double-blind treatment period into the vortioxetine 10-mg group (123 patients), vortioxetine 5-mg group (119 patients), and placebo group (124 patients; Fig. S1 ). Overall, MDD characteristics at baseline of the short-term study were similar between the treatment groups (Table 1a) . A total of 169 patients (46.3%) reported any previous disease, and the percentages of patients with previous disease were similar between the treatment groups (45.2%, 45.4%, and 48.4% in the placebo, vortioxetine 5-mg, and vortioxetine 10-mg groups, respectively). Except for MDD, which was reported by 152 patients as previous disease (38.7%, 41.2%, and 44.3% in the placebo, vortioxetine 5-mg, and vortioxetine 10-mg groups, respectively), no previous diseases were reported in more than two patients in any of the treatment groups.
A total of 28 (7.7%) patients discontinued the double-blind treatment period: seven (5.9%) and 10 (8.1%) patients from the vortioxetine 5-mg and 10-mg groups, respectively, and 11 (8.9%) patients from the placebo group. The most common reasons for discontinuation included a pretreatment event or an AE in a total of 13 patients (46.4%) with three (42.9%), four (40%), and six (54.5%) patients in the vortioxetine 5-mg, vortioxetine 10-mg, and placebo groups, respectively, while a total of eight patients (28.6%) withdrew their consent (two [28.6%] from the vortioxetine 5-mg group, three [30%] from the vortioxetine 10-mg group, and three [27.3%] from the placebo group; Fig. S1 ).
Of 338 patients who completed the 8-week double-blind treatment period, 120 patients enrolled in the long-term study where 119 patients received study medication while one patient was enrolled but did not continue into the treatment phase and did not receive the study medication (Fig. S1) . Patient demographics at baseline of the open-label study were similar to those of the preceding short-term study (Table 1b) . In total, 32 (26.7%) patients prematurely discontinued the long-term study; the most common reasons included an AE in 12 patients (37.5%) and withdrawal of consent in 10 patients (31.3%). Three patients (9.4%) discontinued because of noncompliance, two patients (6.3%) discontinued because of lack of efficacy, and one patient (3.1%) discontinued because of pregnancy (Fig. S1 ).
Efficacy outcomes
For the primary analysis -the change from baseline in MADRS total score after 8 weeks of double-blind treatment -the Fisher's LSD procedure was applied to control type I error. The overall F-test showed that the P-value for the overall effect of treatment was not statistically significant (Table 2) . Numerically greater decreases in MADRS total scores from baseline were observed in the vortioxetine groups than in the placebo group at week 8, but these were not statistically significant ( Table 3 ). The least square (LS) mean differences from placebo (ANCOVA, LOCF) were −2.03 and −1.04 for the vortioxetine 5-mg and 10-mg groups, respectively ( Table 3 ). The secondary analysis using MMRM also yielded numerically greater but statistically not significant decreases in MADRS total scores from baseline after short-term treatment with vortioxetine in the 5-mg and 10-mg groups than placebo ( Table 3 ). The subgroup analysis of patients with baseline MADRS total score ≤ 30 showed changes from baseline in MADRS total score that were similar among treatment groups at week 8, while patients with baseline MADRS total score ≥ 31 showed clinically relevant differences between placebo and the active dose groups (−4.4 and −2.1 in the 5-and 10-mg vortioxetine groups, respectively; Table 4 ). The MADRS cutoff score of greater than 30 is in line with the accepted threshold of severe depression. 15 Similarly, in patients who had a single MDE, changes from baseline in MADRS total score were similar among treatment groups. Clinically relevant differences between placebo and active dose groups were observed in patients with recurrent MDE (−4.7 and −2.8 with 5 and 10 mg vortioxetine, respectively; Table 4 ). Numerically higher MADRS remission and response rates, and numerically greater decreases from baseline in HAM-D17 total score, SDS total score, and CGI-I score were observed in the vortioxetine groups than in the placebo group at week 8 ( Table 5 ). The MADRS total score improved over the 52-week treatment period, with mean values decreasing from 14.8 at the baseline of the long-term study to 4.9 at week 52 (Fig. 2a) . Global patient functioning, assessed by the CGI-I and CGI-S scores, also showed continuous improvement over 52 weeks (Fig. 2b) .
Safety outcomes
During the 8-week, double-blind treatment period, a total of 251 (68.8%) patients reported at least one TEAE, with 80 (67.2%) and 93 (76.2%) patients in the vortioxetine 5-mg and 10-mg groups, respectively, and 78 (62.9%) patients in the placebo group. Most TEAE were mild (transient and easily tolerated by the patient) to moderate in severity (Table 6a ). The only event with incidences above 5% and ≥ twofold higher in both treatment groups (16.8% and 28.7% in the vortioxetine 5-mg and 10-mg groups, respectively) than in the placebo group (7.3%) was nausea. Only suicidal behavior was considered to be possibly related to the study drug.
A total of 103 patients (86.6%) experienced at least one TEAE during the long-term study (Table 6b ). Most TEAE were mild or moderate in severity in 68.1% and 16.8% of patients, respectively. TEAE with incidences ≥ 10% were nasopharyngitis (40.3%), nausea (21.0%), seasonal allergy (11.8%), and headache (10.9%).
Nausea was also the most common drug-related TEAE in the long-term study. All nausea events were mild (21 patients) or moderate (four patients) in intensity. Two patients discontinued the study because of nausea. Of the 25 patients (21%) who reported nausea during the 52-week, open-label treatment period, 13, four, and eight patients had received placebo, 5 mg vortioxetine, and 10 mg vortioxetine, respectively, during the preceding doubleblind treatment period. Onset of nausea during the first 2 weeks of the long-term treatment period was reported in eight, one, and four patients in the placebo, vortioxetine 5-mg, and vortioxetine 10-mg groups, respectively.
In the long-term study, suicidal ideation was experienced in five patients, of which one case was reported as a serious TEAE leading to discontinuation. This TEAE was considered to be not related to the study drug. There was no clinically meaningful trend in C-SSRS results during the study, and no TEAE related to sexual dysfunction were reported. Mean laboratory values, vital signs, and ECG parameters did not show clinically relevant changes, and the incidences of clinically significant changes were generally low. Ten patients (8.4%) reported weight increase as a TEAE, and seven patients had weight increases considered to be related to the study drug. All weight increases were mild in intensity. There were no deaths during either study.
DISCUSSION
Here we report the results of a short-term randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two fixed doses of vortioxetine (5 and 10 mg) and of the subsequent 52-week extension study to assess The mean changes from baseline in MADRS total score were compared between treatment groups using an overall F-test based on an ANCOVA model with the change in MADRS total score as a dependent variable, treatment as a fixed effect, and the baseline MADRS total score as a covariate. ANCOVA, analysis of covariance; FAS, full analysis set; LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Depression Rating Scale.
long-term safety and efficacy of flexible doses of 5, 10, and 20 mg vortioxetine in Japanese MDD patients. Although vortioxetine treatment led to numerically greater decreases in MADRS total score after 8 weeks, the study failed to show statistical significance over placebo on the primary end-point. The 52-week extension study showed continued improvements in MADRS total score during the study.
In non-Japanese patients with MDD, the efficacy of vortioxetine at a dose range between 5 and 20 mg/day has been demonstrated in multiple phase 3 studies. 13, 14, 16, 17 In a phase 2 study with a subpopulation of Japanese patients, the highest dose was 20 mg/day. 18 However, in previous phase 2 and phase 3 studies, a dose-dependent increase of incidences of nausea was observed while the 10-mg/day dose showed comparable or greater efficacy while being well tolerated. 14, 19 In addition, 5 mg/day vortioxetine was efficacious and well tolerated in elderly patients (mean age of 70.6 years) with recurrent MDD. 20 An effort to avoid excluding elderly patients Change from baseline in MADRS total score at week 8 (LOCF) was the primary efficacy end-point of the short-term study. ANCOVA, analysis of covariance; CI, confidence interval; LOCF, last observation carried forward; LS mean, least square mean; MADRS, Montgomery-Åsberg Depression Rating Scale; MMRM, mixed model for repeated measurements; PBO, placebo; SE, standard error; VOR, vortioxetine. The mean change from baseline in MADRS total score at week 8 (LOCF) was performed in terms of MADRS total score at baseline and status of major depressive episode. CI, confidence interval; FAS, full analysis set; LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Depression Rating Scale; PBO, placebo; VOR, vortioxetine.
was made in the current study with the upper age range for inclusion set at 75 years instead of the more common 65 years. In addition, a randomized, double-blind 8-week study comparing the efficacy and tolerability of 10 mg vortioxetine and 150 mg venlafaxine over 8 weeks in Asian MDD patients showed that vortioxetine was safe and at least as effective as venlafaxine with a numerical advantage on the MADRS of 1.2 points. 21 It is important to note that while the subgroup analyses suggest that patients with baseline MADRS total score ≥ 31 showed clinically relevant differences between placebo and the active dose groups, these results should be viewed as exploratory considering the population size and original study design.
The open-label extension study was the first phase 3 trial to evaluate long-term safety and efficacy of flexible doses of 5, 10, or 20 mg/day vortioxetine in Japanese patients with MDD. A total of 26.7% of patients prematurely discontinued this long-term study, compared with approximately 40-50% of MDD patients who discontinued other 52-week open-label extension studies conducted in Europe/ Asia or the USA. 19, 22 Common reasons for withdrawal were similar to previous studies with nonJapanese MDD patients. 22 Only patients who showed some response to the preceding short-term treatment were eligible to enter this open-label extension study. Therefore, this study design differs from that of other open-label extension studies in non-Japanese patients that allowed all patients who completed the preceding double-blind treatment period to enter the extension phase and may account for the lower discontinuation rate. 19 The safety profile of vortioxetine was similar in Japanese MDD patients compared with nonJapanese patients. The safety data after 8 weeks were consistent with results of other previous short-term studies evaluating vortioxetine in non-Japanese patients. 19 In this long-term extension study, vortioxetine showed good safety profile for all doses. There was no evidence of any TEAE unique to longterm treatment with vortioxetine. The incidence of serious TEAE (3.4%) in the long-term study was similar to other long-term studies in non-Japanese MDD patients. The tolerability profile from these studies, including the reported TEAE, suggests that vortioxetine has a similar safety profile in Japanese and non-Japanese MDD patients. 19 Nausea reports were comparable with non-Japanese MDD patients on vortioxetine treatment. Mild or moderate nausea was one of the most commonly reported AE in the long-term study and had the highest incidence of drug-related TEAE. Other completed long-term studies in non-Japanese MDD patients have reported similar trends with nausea as an AE. 19 Nausea was also the primary TEAE that caused discontinuation, which has been observed with other long-term studies as well. 19, 23 Onset of nausea was mostly observed during the first 90 days of treatment in the long-term study, especially in patients who received placebo during the preceding short-term study. This finding indicates that the nausea events could have been associated with treatment initiation.
No difference from non-Japanese MDD patients was observed in common AE associated with antidepressants, such as weight gain/metabolic disturbance or sexual dysfunction. [24] [25] [26] [27] In the longterm study, the mean bodyweight increased over time. While weight increase as an AE was reported in 10 patients, bodyweight increase and decrease of ≥ 7% from baseline was reported in 34 patients (28.6%) and 11 patients (9.2%), respectively. Both incidences were slightly higher than those of other studies. 19 However, it is difficult to distinguish between untoward events and improvement in the underlying disease. The MADRS total score decreased in line with increasing bodyweight in this long-term study, so the weight gain might be associated with the improved depressive symptoms. No TEAE related to sexual dysfunction were reported in either study.
Although both the short-term and extension studies showed numerical improvements in MADRS scores, this improvement did not reach the level of statistical significance. Factors that could have potentially played a role in the failure to achieve statistical significance could include the placebo response, which is an increasingly relevant issue in antidepressant clinical trials. The placebo response in antidepressant trials currently averages 31% and has been increasing at a rate of 7% per decade for TEAE were collected from visit 2 through visit 9 or early termination in patients who did not participate in the long-term extension study, and from visit 2 through visit 7 in patients who participated in the long-term extension study. TEAE, treatment-emergent adverse event. the last 30 years. 28 It is also important to note the possible limitations of these current studies, which include the exclusion of the approved 20-mg vortioxetine dose in the short-term study and the use of an age range that skews slightly older, unlike clinical trials that typically include patients aged between 18 and 65 years with up to 35% of published trials excluding older populations completely. 29 In conclusion, short-and long-term treatment with vortioxetine at doses that are currently approved for treatment in non-Japanese MDD patients, ranging between 5 and 20 mg/day, was safe and welltolerated in Japanese patients with MDD. Further studies are required to evaluate the efficacy of vortioxetine in Japanese patients with MDD.
